Immunocore appoints Travis Coy, previously a Non-Executive Director, as its EVP, Chief Financial Officer and Head of Corporate Development
January 02 2025 - 6:00AM
Immunocore appoints Travis Coy, previously a
Non-Executive Director, as its EVP, Chief Financial Officer and
Head of Corporate Development
(OXFORDSHIRE, England & CONSHOHOCKEN, Penn.
& GAITHERSBURG, Md., US, 02 January 2025) Immunocore Holdings
plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a
commercial-stage biotechnology company pioneering and delivering
transformative immunomodulating medicines to radically improve
outcomes for patients with cancer, infectious diseases and
autoimmune diseases, today announces that Travis Coy has been
appointed as Executive Vice President (EVP), Chief Financial
Officer and Head of Corporate Development, effective January 1,
2025. He will become an Executive Officer, transitioning from his
role of Non-Executive Director that he assumed in September
2019.
Travis brings with him over 20 years of
experience working at Eli Lilly and Company, where his most recent
role was Vice President, Head of Transactions and M&A,
Corporate Business Development. Prior to this role, Travis held a
variety of roles, at Eli Lilly, of increasing responsibility across
finance and business development, including leading business
development for oncology and cardiometabolic diseases, financial
leadership of the oncology business unit, Director of Investor
Relations, and Director of Corporate Finance and Investment
Banking. He started his career as a chemist in Lilly’s research
laboratories. Travis holds an MBA from the Ross School of Business
at the University of Michigan and a BS in Chemistry from
Rose-Hulman Institute of Technology.
"I am delighted to welcome Travis to the
Executive team," said Bahija Jallal, Chief Executive
Officer of Immunocore. “Having served as a Non-Executive
Director for 5 years, his deep knowledge of our company and science
will be invaluable in his new role as we continue delivering on our
mission to transform outcomes for patients.”
“I want to thank Travis for his service on the
Board of Immunocore, and in particular his leadership on the Audit
Committee,” said Professor Sir John Bell, Chairman of the
Board of Immunocore. “I look forward to continuing working
with him in his CFO role.”
"I am excited to transition from my position as
a Board member of Immunocore to now lead the Finance and Corporate
Development functions," said Travis Coy, Immunocore's new
Chief Financial Officer. "I look forward to partnering
with the other members of the Executive team to deliver
transformative medicines to patients with cancer, infectious
diseases and autoimmune diseases with our differentiated platform
and strong financial base."
About Immunocore
Immunocore is a commercial-stage biotechnology
company pioneering the development of a novel class of TCR
bispecific immunotherapies called ImmTAX – Immune mobilizing
monoclonal TCRs Against X disease – designed to treat a broad range
of diseases, including cancer, autoimmune diseases and infectious
diseases. Leveraging its proprietary, flexible, off-the-shelf
ImmTAX platform, Immunocore is developing a deep pipeline in
multiple therapeutic areas, including nine active clinical and
pre-clinical programs in oncology, infectious diseases, and
autoimmune diseases. The Company’s most advanced oncology TCR
therapeutic, KIMMTRAK, has been approved for the treatment of
HLA-A*02:01-positive adult patients with unresectable or metastatic
uveal melanoma in the United States, European Union, Canada,
Australia, and the United Kingdom.
Forward Looking Statements
This press release contains “forward-looking
statements” within the meaning of the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. Words such as
“may”, “will”, “believe”, “expect”, “plan”, “anticipate” and
similar expressions (as well as other words or expressions
referencing future events or circumstances) are intended to
identify forward-looking statements. All statements, other than
statements of historical facts, included in this press release are
forward-looking statements. These statements include, but are not
limited to, statements regarding the ability of the Company’s
ImmTAX platform to address a broad range of cancers, infectious
diseases and autoimmune diseases; and the Company’s ability to
deliver transformative medicines to patients. Any forward-looking
statements are based on management’s current expectations and
beliefs of future events and are subject to a number of risks and
uncertainties that could cause actual events or results to differ
materially and adversely from those set forth in or implied by such
forward-looking statements, many of which are beyond the Company’s
control. These risks and uncertainties include, but are not limited
to, the impact of worsening macroeconomic conditions on the
Company’s business, financial position, strategy and anticipated
milestones, including Immunocore’s ability to conduct ongoing and
planned clinical trials; Immunocore’s ability to obtain a clinical
supply of current or future product candidates or commercial supply
of KIMMTRAK or any future approved products, including as a result
of health epidemics or pandemics, war in Ukraine, the conflict in
the Middle East or global geopolitical tension; Immunocore’s
ability to obtain and maintain regulatory approval of its product
candidates, including KIMMTRAK; Immunocore’s ability and plans in
continuing to establish and expand a commercial infrastructure and
to successfully launch, market and sell KIMMTRAK and any future
approved products; Immunocore’s ability to successfully expand the
approved indications for KIMMTRAK or obtain marketing approval for
KIMMTRAK in additional geographies in the future; the delay of any
current or planned clinical trials, whether due to patient
enrollment delays or otherwise; Immunocore’s ability to
successfully demonstrate the safety and efficacy of its product
candidates and gain approval of its product candidates on a timely
basis, if at all; competition with respect to market opportunities;
unexpected safety or efficacy data observed during preclinical
studies or clinical trials; actions of regulatory agencies, which
may affect the initiation, timing and progress of clinical trials
or future regulatory approval; Immunocore’s need for and ability to
obtain additional funding, on favorable terms or at all, including
as a result of worsening macroeconomic conditions, including
changes in inflation and interest rates and unfavorable general
market conditions, and the impacts thereon of the war in Ukraine,
the conflict in the Middle East, and global geopolitical tension;
Immunocore’s ability to obtain, maintain and enforce intellectual
property protection for KIMMTRAK or any of its product candidates
it or its collaborators are developing; and the success of
Immunocore’s current and future collaborations, partnerships or
licensing arrangements. These and other risks and uncertainties are
described in greater detail in the section titled "Risk Factors" in
Immunocore’s filings with the Securities and Exchange Commission,
including Immunocore’s most recent Annual Report on Form 10-K for
the year ended December 31, 2023 filed with the Securities and
Exchange Commission (SEC) on February 28, 2024, as well as
discussions of potential risks, uncertainties, and other important
factors in the Company’s subsequent filings with the SEC. All
information in this press release is as of the date of the release,
and the Company undertakes no duty to update this information,
except as required by law.
Contact Information
Immunocore Sébastien Desprez,
Head of CommunicationsT: +44 (0) 7458030732E:
sebastien.desprez@immunocore.comFollow on Twitter: @Immunocore
Investor RelationsClayton
Robertson, Head of Investor RelationsT: +1 (215) 384-4781E:
ir@immunocore.com
Immunocore (NASDAQ:IMCR)
Historical Stock Chart
From Dec 2024 to Jan 2025
Immunocore (NASDAQ:IMCR)
Historical Stock Chart
From Jan 2024 to Jan 2025
